NCT00162110View on ClinicalTrials.gov

A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2007

Conditions
Mucinous Gastrointestinal Adenocarcinoma
Interventions
DRUG

cetuximab

mg, IV, 225 mg/m2, weekly, 4-52 weeks depending on response.

Trial Locations (2)

Unknown

Local Institution, New York

Local Institution, Cincinnati

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT00162110 - A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces | Biotech Hunter | Biotech Hunter